NAD+
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
Best fit for depleted or over-35 users chasing NAD+ restoration for mitochondrial support, DNA-repair substrate availability, post-illness recovery, metabolic resilience, or healthy-aging maintenance.
Active cancer is an absolute contraindication; morning-only dosing is essential as evening administration causes prolonged inability to sleep.
Best fit for depleted or over-35 users chasing NAD+ restoration for mitochondrial support, DNA-repair substrate availability, post-illness recovery, metabolic resilience, or healthy-aging maintenance. It is not a stimulant-like energy tool.
Active malignancy is the hard stop. Evening dosing can cause prolonged insomnia. IV infusion causes rate-dependent flushing, chest pressure, dyspnea, cramping, and nausea when pushed too fast; SubQ use commonly burns at the injection site because of acidity. High-dose oral NMN can cause GI discomfort, and chronic very-high-dose use above roughly 2000mg/day carries a precautionary renal concern that is not established in trials.
NAD+ is a high-value mitochondrial and longevity tool when the user is actually depleted: older age, post-viral fatigue, burnout, metabolic dysfunction, chronic inflammation, or low intracellular NAD+ testing. Oral NMN/NR is the low-friction maintenance path; IV or SubQ NAD+ is the higher-cost restoration path with a stronger acute experiential signal. Healthy young users should expect subtle maintenance effects, not a dramatic transformation.
High in depleted populations, especially post-illness, over-40, metabolic dysfunction, burnout, and chronic fatigue contexts. Moderate in healthy young users, where the effect is usually subtle and gradual. IV is consistently perceived as stronger than oral, while oral NMN commonly appears to plateau around the 500-750mg/day range unless testing shows severe depletion. The article's most important efficacy split is not NMN vs NR; it is depleted user vs already-healthy optimizer, and injectable vs oral.
Do not use with active malignancy — NAD+ fuels rapidly dividing tumor cells via the same pathways it restores in healthy tissue.
Intro
NAD+ (nicotinamide adenine dinucleotide) is the universal cellular electron carrier — a coenzyme required for over 500 enzymatic reactions including every major metabolic pathway, DNA repair, immune signaling, and circadian regulation. Its role splits between redox chemistry (accepting/donating electrons in glycolysis, the TCA cycle, and beta-oxidation) and non-redox substrate function: sirtuins, PARPs, and CD38 all consume NAD+ irreversibly as their reaction substrate.
NAD+ levels decline approximately 50% by age 50 in humans, though the data is most consistent for skeletal muscle and blood — tissue-specific declines in brain and liver are less established in human studies and primarily demonstrated in animal models. The practical implication is compound: NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in NAD+ biosynthesis, also declines with age, creating a double deficit of both falling production and continued consumption.
The critical clinical distinction that practitioners have converged on: responses to NAD+ supplementation differ fundamentally between healthy athletes and dysfunctional/sick individuals. Athletes with intact NAMPT and low CD38 activity simply need substrate — their biosynthetic machinery is functional. Dysfunctional patients (chronic inflammation, metabolic syndrome, post-illness) have upregulated CD38, impaired NAMPT, and active NNMT drainage creating three simultaneous NAD+ leaks. Supplementing NAD+ without addressing these upstream drains is described by practitioners as 'filling a leaking bucket.' The response profile, dose requirements, and expected timeline differ substantially between these populations.
Observed Effects
NAD+ supplementation produces a characteristic set of effects with a consistent hierarchy across community and clinical reports. Response magnitude is strongly predicted by the athlete-vs-dysfunctional framework: depleted or sick individuals experience the most dramatic changes.
Energy and mitochondrial restoration is the primary reported effect, described consistently as "cleaner than caffeine, sustained for days" following IV infusion. The multi-day duration (2-5 days post-infusion) distinguishes it from stimulant effects and suggests genuine mitochondrial upregulation. Oral NMN/NR produces a more gradual energy plateau over 2-4 weeks rather than an acute peak. Effect is universal across user populations; most pronounced in the depleted (60+, post-illness, chronic fatigue).
Sleep quality improvement — deeper sleep, reduced fragmentation, vivid dreaming — is consistently reported across multiple community accounts. IV effects appear the next night after infusion; oral forms within 1-2 weeks. Vivid dreaming indicates REM improvement. Mechanism likely involves SIRT1 influence on circadian clock genes and melatonin synthesis. The paradox: this same mitochondrial upregulation causes insomnia if dosed in the evening — morning-only timing is therefore non-negotiable.
Cognitive clarity ("brain fog lifting," improved processing speed) is moderate in strength, most pronounced in depleted individuals with Long COVID, burnout, or chronic fatigue. IV onset is within hours, lasting 2-4 days; oral is gradual over weeks. Distinct from dopaminergic or stimulant mechanisms.
Athletic recovery improvement is moderate — community reports show DOMS duration reduced from 48-72 hours to 24-36 hours with consistent supplementation. Most relevant in recovery-limited athletes; marginal in highly optimized individuals. Effects emerge within 2-4 weeks.
Metabolic benefits (glucose, lipid, insulin sensitivity improvements) are moderate in metabolically impaired populations and demonstrated in multiple RCTs for metabolic syndrome, T2D, and aging populations. Biomarker changes require 8-12 weeks. Effects are more pronounced in metabolically impaired vs healthy individuals.
Post-illness recovery is the highest-response indication documented. Practitioners report 80% subjective response rate in post-COVID fatigue patients with IV NAD+ protocols. Post-illness, overtraining syndrome, and burnout represent the clearest clinical use case, typically requiring 4-8 IV sessions for meaningful recovery.
Intracellular NAD+ elevation is measurable via Jinfiniti DBS testing. Community n=1 data shows baseline 18.4 µM rising to 45.3 µM after 60 days at 1g NMN/day (Jake's Journey). Optimal range reported as 40-60 µM. Diminishing returns above 500mg/day oral are consistent with NAMPT rate-limiting — testing reveals this ceiling and guides dose optimization.
Field Reports
The experiential signature of IV NAD+ is distinctive and widely documented: 'cleaner than caffeine, sustained for days' is the community consensus descriptor for the post-infusion energy quality.
The IV rush (flushing, chest pressure, muscle cramping during infusion) has become its own community knowledge base — experienced users know to request slow drip rates, avoid combo bags with glutathione, and plan for the temporary discomfort as a threshold to the benefit.
Long COVID and post-viral fatigue patients represent the community's most compelling case series: multiple detailed first-person accounts document significant recovery from 2+ year chronic fatigue syndromes after IV NAD+ loading protocols, with specific symptom timelines and functional improvements. This is the highest-response indication in community reports and aligns with the mechanistic understanding of post-viral mitochondrial dysfunction.
Jakesjourney.co's rigorous n=1 remains one of the clearest community data points: baseline Jinfiniti at 18.4 µM (severely depleted) rising to 45.3 µM after 60 days at 1g NMN/day, with correlated subjective improvements. The measured response to a specific dose in a verified-depleted individual is the kind of evidence clinical trials struggle to produce for individual-level guidance.
Vanja Petreski's 'The NAD+ Rush' documents the IV experience with specific clinical detail — describing the infusion side effects with enough specificity that it functions as preparation for first-time IV users. The 5-7 day mood improvement documented post-IV suggests a sustained neurochemical or mitochondrial mechanism rather than just acute pharmacology.
Scott K's four-product oral comparison (NAD3, NR, NMN, oral NAD+) showing 'identical subjective effects' across all oral forms reinforces the community position that the meaningful variable is injectable vs oral, not which oral form.
Community Consensus
NAD+ sits in the unusual middle ground where clinical mechanism, consumer self-testing, and practical clinic experience mostly point in the same direction: NAD+ biology matters, but the strongest visible response belongs to depleted users rather than already-optimized healthy users. The clinical literature is strongest for mechanism, NAD+ precursor pharmacology, and metabolic endpoints; the community is strongest for route comparison, timing rules, tolerability, and dose-response testing.
The dominant consensus frame is the athlete-vs-dysfunctional split. A healthy athlete with intact NAMPT and low inflammatory CD38 activity often needs only modest precursor substrate. A chronically inflamed, metabolically impaired, post-viral, or older user may have multiple active drains at once: lower NAMPT production, higher CD38 consumption, and NNMT diversion. That is why the same oral NMN dose can feel subtle in one person and transformative in another.
The strongest practical consensus is injectable vs oral, not NMN vs NR. Oral NMN/NR is the maintenance and prevention lane; IV and, to a lesser extent, SubQ NAD+ are the restoration lanes when the user is depleted enough to justify cost, discomfort, and oversight. The repeated community take is bullish but bounded: NAD+ is worth attention when depletion is plausible, but it is easy to overspend if the user never tests, ignores upstream drains, or expects healthy-young-user effects to look like post-illness recovery.
Regulatory uncertainty around NMN has made sourcing a live topic. The useful takeaway is not to chase exotic forms; it is to use third-party-tested oral products, pharmacy-grade material for IV, and measured response where possible. Intracellular NAD+ testing has made this area more accountable than most longevity supplementation because users can confirm whether a protocol raised the target pool rather than relying only on energy or mood.
Risks & Monitoring
NAD+ is well-tolerated when used correctly, but each delivery route carries route-specific adverse effects. The most clinically significant safety issue is the absolute contraindication with active malignancy.
NAD rush — flushing, chest pressure/tightness, dyspnea, muscle cramping, nausea — is the most dramatic adverse effect and occurs universally with IV infusion at standard or fast rates. It is a rate-dependent vasodilation and histamine release phenomenon, not a true allergic reaction. Management is straightforward: slow the infusion rate to 2-4 hours for 250mg (longer for higher doses). Never combine glutathione or vitamin C in the same IV bag — this intensifies the reaction. MCAS patients require H1+H2 antihistamine pretreatment (cetirizine + famotidine). The rush is uncomfortable but rarely dangerous in otherwise healthy individuals; rate management eliminates it in most cases.
SubQ injection site burning is near-universal, intense (lasting 20-60 minutes), and caused by the highly acidic pH of reconstituted NAD+ solution. This is not a sign of poor technique — it is intrinsic to the formulation. Sodium bicarbonate buffering (1:1 mix with reconstituted NAD+), 29-gauge minimum needle, very slow push rate (30+ seconds), and site rotation reduce but do not eliminate burning. Discomfort decreases substantially by the 5th injection as technique improves and users acclimate.
Insomnia and overstimulation occur reliably when any form of NAD+ is dosed in the afternoon or evening. NAD+-driven mitochondrial upregulation produces sustained ATP synthesis that disrupts sleep architecture. Morning-only dosing (all forms before noon) is the universal solution. This is the most commonly violated protocol rule among new users.
GI discomfort (nausea, cramping) occurs in approximately 20-30% of users at doses ≥1000mg/day oral NMN. Caused by high local concentrations from large single doses. Management: split dosing (2×500mg or 4×250mg), take with small meals, start at 250mg and escalate over 2-4 weeks.
Post-infusion fatigue ("NAD crash") — 1-4 hour fatigue after IV sessions — affects approximately 15-20% of first-time IV users and diminishes after initial loading sessions. Hypothesized mechanism: sudden NAD+ availability triggers massive sirtuin and PARP activity that temporarily depletes energy. Plan IV sessions for low-demand days; resolves spontaneously.
Anxiety and overstimulation at higher oral doses are dose-dependent and manageable with reduction to 300-500mg/day and strict morning timing.
Potential renal concern with very high-dose chronic NMN is a community harm-reduction signal only — not documented in clinical trials at doses ≤1000mg/day. Community precautionary guidance recommends staying below 2000mg/day long-term. This risk is speculative and should not deter use at standard doses.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
The only validated consumer tool for measuring intracellular NAD+ status. Establishes true baseline depletion depth, guides dose selection, and distinguishes responders from non-responders. Optimal range: 40-60 µM. Also distinguishes if CD38/NNMT management is needed first.
Renal function baseline before starting NMN supplementation given the precautionary community signal about high-dose chronic use. Glucose and electrolytes relevant for metabolic context.
NMN has shown lipid improvements in clinical trials — useful baseline to track response, especially in metabolically compromised users where lipid improvement is a therapeutic goal.
NAD+ precursors improve insulin sensitivity in clinical trials. Baseline HbA1c is useful for tracking metabolic improvement over 3-6 months.
Retest at 8-12 weeks to confirm supplementation is elevating intracellular NAD+. Identifies non-responders who may need CD38 management (quercetin + apigenin) added before NAD+ loading.
Monitor liver enzymes (AST, ALT, ALP) at first follow-up for users taking high-dose oral NMN and stacking with other hepatotoxic compounds. Not specifically indicated by NAD+ mechanism but standard monitoring practice.
Avoid With
Do not combine NAD+ with the following. Sorted highest-severity first.
Why:NAD+ fuels rapidly dividing cells including tumor cells — the same metabolic machinery that restores healthy cell function can accelerate tumor proliferation. CD38 is overexpressed in multiple myeloma and other hematologic malignancies.
What to do:Universal hard contraindication across all practitioners and community sources. Active cancer = hard stop on NAD+ supplementation.
Why:Combining in the same IV bag intensifies the vasodilatory/histamine 'rush' reaction significantly — creates a more intense and harder-to-manage reaction than either compound alone.
What to do:Administer sequentially (before or after), never simultaneously in the same infusion bag.
Why:Metformin inhibits mitochondrial Complex I, shifting NAD+:NADH ratio toward NADH and reducing free NAD+ availability. Leads to blunted response to NAD+ supplementation unless higher doses are used.
What to do:Not a contraindication — but patients on metformin should start NMN at higher doses (minimum 1000mg/day oral) and consider injectable routes due to the Complex I depletion.
Protocols By Goal
Healthy aging / longevity optimization. Reported oral NMN/NR use often starts in the 300-500 mg/day morning range, with higher-impact routes reserved for users who have documented depletion, meaningful symptoms, or clinician oversight. Younger healthy users should expect subtle, gradual benefits rather than dramatic acute effects.
Over-35 optimization with declining energy, recovery, and cognition. Reports often combine oral NMN/NR with periodic injectable or IV exposure, especially when baseline testing suggests depletion. CD38-management supplements are sometimes used before escalation in inflamed or metabolically dysfunctional users.
Post-illness recovery. Practitioner reports describe IV-heavy loading for Long COVID, burnout, and overtraining contexts, sometimes bridged with oral or SubQ use. This is high-stakes clinician-context material and should remain framed as observational adjunctive care, not a self-treatment protocol.
Metabolic dysfunction or metformin use. Reports emphasize addressing inflammatory and metabolic NAD+ drains before simply escalating dose. Testing is useful because users can otherwise misread poor response as product failure.
Athletic performance. Reports describe injectable or oral maintenance for recovery and sustained energy rather than direct stimulant-like performance.
Addiction recovery support. Intensive IV NAD+ protocols exist in supervised treatment settings as adjunctive care. They are not standalone addiction treatment and should not be translated into home-use instructions.
Dosing Details
NAD+ supplementation spans four delivery routes with different bioavailability, cost, and risk: IV, SubQ, sublingual, oral NMN, and oral NR.
Practitioners generally treat IV as the highest-impact acute route, SubQ as an intermediate injectable route, and oral NMN/NR as the simpler maintenance lane. This section describes observed practice, not instructions.
IV reports commonly involve 250-1000 mg sessions in supervised clinical settings because rate-related flushing, chest pressure, dyspnea, cramping, and nausea can be dramatic. SubQ reports commonly discuss around 100 mg per injection with local burning as the main tolerability issue. Oral NMN/NR reports usually sit in the 250-1000 mg/day range with morning dosing because evening use often disrupts sleep.
Route choice changes the risk class. Oral supplement quality problems are usually tolerability/value problems; IV impurity, rate, and access problems can be clinically meaningful. Public prose should not provide home-IV or reconstitution instructions.
Stacks & Alternatives
Core mitochondrial dual stack. MOTS-c activates AMPK via a different pathway than NAD+/sirtuins — same downstream PGC-1α target, different upstream entry point. Complementary, not redundant. NAD+ restores ETC substrate and feeds sirtuin pathway; MOTS-c activates AMPK-driven mitochondrial biogenesis independently.
NNMT inhibitor specifically in adipose tissue — blocks the methylation drain on nicotinamide in fat tissue without affecting liver methylation. Preserves nicotinamides for NAD+ synthesis in adipose, increases intracellular NAD+/NADH/NADP+/NADPH in adipose. Critical addition for metabolically dysfunctional patients and body composition goals.
Complementary mitochondrial compound targeting ETC protection (cardiolipin stabilization) rather than substrate restoration. NAD+ provides the fuel; SS-31 protects the machinery. Most valuable combination for healing/recovery rather than pure optimization.
CD38 inhibitors — prerequisite for dysfunctional patients. Quercetin 500mg/day + apigenin 50mg/day (from Sophora japonica) lower CD38 activity, preventing the 'leaking bucket' scenario where supplemented NAD+ is immediately consumed by elevated CD38.
Provides riboflavin (FAD/FMN for ETC), niacin (NAD+ precursor), B6, folate, B12 — cofactors for NAD+-dependent enzymatic reactions and mitochondrial function. Ensures the downstream reactions NAD+ enables can run at full capacity.
Master antioxidant support — reduces oxidative stress generated by increased mitochondrial activity. Addresses the ROS production that increases with enhanced mitochondrial function. Community standard stack alongside NAD+ protocols.
Electron carrier that can directly donate electrons to Complex IV, bypassing upstream ETC bottlenecks. Cognitive enhancement and mitochondrial optimization via a completely different mechanism than NAD+. Complementary rather than redundant.
Methyl donor — counteracts methylation drain from NNMT activity. Supports hepatic glutathione synthesis via the methionine cycle. Adds methyl group availability when NNMT is diverting nicotinamide out of NAD+ salvage.
Alternatives
Stack Cost
NAD+ is light hormonally but not frictionless: the tax comes from route choice, cancer exclusion, morning-only timing, testing/cost discipline, and avoiding IV rush or SubQ tolerability failures.
The article treats active malignancy as the non-negotiable hard stop because NAD+ supports rapidly dividing cells through the same energetic machinery it restores in healthy tissue.
Oral NMN/NR is simple, but the article's higher-impact routes require clinical IV rate management or SubQ reconstitution, buffering, injection technique, and tolerance for injection-site burning.
The article repeatedly flags evening dosing as a reliable insomnia trigger across routes. The burden is not psychiatric complexity; it is strict timing discipline.
Jinfiniti testing is not mandatory for casual oral use, but the article makes baseline and 8-12 week retesting the best way to avoid blind escalation, identify non-response, and decide whether CD38/NNMT management is needed.
The article's strongest experiential lane is IV, which costs hundreds per session and requires pharmacy-grade material. Oral products are cheaper but create regulatory and product-quality questions around NMN.
- ·Treat oral NMN/NR as a low-friction longevity maintenance lane, not a high-drama protocol.
- ·Reserve IV or frequent SubQ NAD+ for documented or plausible depletion: post-illness fatigue, older age, metabolic dysfunction, burnout, or low intracellular NAD+ testing.
- ·Do not stack same-bag IV NAD+ with glutathione or vitamin C; if those are used, separate the administrations.
- ·If active malignancy is present, NAD+ does not get a stack slot at all.
- ·If a user is on metformin or has metabolic syndrome, address CD38/NNMT drains and verify response instead of assuming higher NAD+ dosing fixes the bottleneck.
- ·Morning-only dosing rule across oral, SubQ, and IV routes.
- ·Baseline and follow-up intracellular NAD+ testing when the protocol is expensive, high-dose, injectable, or aimed at recovery from depletion.
- ·BMP/CMP or renal/metabolic baseline for high-dose oral use, metabolic dysfunction, or complex stacks.
- ·IV rate management and separate administration of glutathione or vitamin C.
- ·SubQ injection supplies, optional bicarbonate buffering, and site rotation if using home injections.
Oral NMN/NR is beginner-accessible if the user avoids evening dosing and does not treat subtle effects as failure. Injectable routes are intermediate because mistakes show up as IV rush, painful SubQ injections, cost waste, or poor sourcing judgment.
- ·Active cancer or unresolved malignancy concern.
- ·MCAS or strong histamine-reactivity history with planned IV use.
- ·Trying to self-administer IV NAD+ or use non-pharmacy-grade material intravenously.
- ·Using frequent SubQ injections without reconstitution and sterile technique competence.
- ·Expecting NAD+ to substitute for sleep, calories, training-load management, or medical evaluation of fatigue.
The article describes no HPG suppression, withdrawal, taper requirement, or rebound physiology. Stopping mainly removes the energy/metabolic support and any active restoration effect.
- ·Return of baseline fatigue or slower recovery if depletion remains.
- ·Loss of IV/subQ acute benefit between sessions.
- ·Need to reassess upstream drains if testing did not improve despite use.
Treat active malignancy as an exclusion, not a monitoring problem. Resolve oncology status before considering NAD+ support.
Slow IV rate, separate antioxidant infusions, use clinical oversight for IV, and use buffering/site rotation/slow push for SubQ.
Use baseline and follow-up testing when the protocol becomes expensive or high-dose; otherwise keep oral dosing conservative and judge value by realistic expectations.
Move all dosing before noon, reduce dose if overstimulation persists, and avoid adding other stimulating mitochondrial compounds late in the day.
The article's hard-stop mechanism is direct: NAD+ can support the metabolism of rapidly dividing tumor cells.
IV NAD+ rush is rate- and histamine-like; the article calls for H1/H2 pretreatment and careful infusion management in this population.
The womenConsiderations section treats pregnancy as precautionary avoidance because human safety data is insufficient.
These contexts may blunt response unless upstream drains are addressed and testing confirms the NAD+ pool is actually improving.
Practical Setup
Baseline testing. Intracellular NAD+ testing is often used before expensive protocols to distinguish adequate, moderate-depletion, and severe-depletion states. The practical value is avoiding both unnecessary escalation and underpowered protocols in genuinely depleted users.
Dysfunctional patients. Chronic inflammation, metabolic syndrome, cancer history, and metformin use can increase NAD+ drain. Reports often address CD38/NNMT-related drains before high-dose loading.
Morning-only rule. Across forms and routes, evening NAD+ support commonly worsens insomnia.
IV access and quality. IV NAD+ belongs in supervised clinical settings with appropriate pharmaceutical-quality material and rate management. Home-IV instructions, sourcing routes, and compounding workarounds should not appear in public prose.
Oral NMN/NR. NMN regulatory status varies and continues to evolve. The reader-facing concern is third-party testing, product legitimacy, and realistic expectations; NR is generally the more conventionally supplement-regulated precursor.
Cost reality. Meaningful NAD+ optimization can be expensive. Value depends heavily on whether the user is depleted/sick versus already healthy.
Mechanism Deep Dive
NAD+ functions through two mechanistically distinct roles:
Redox chemistry (non-consuming): NAD+ accepts electrons (becoming NADH) in catabolic reactions — glycolysis, the TCA cycle, beta-oxidation, and amino acid metabolism. NADH then donates electrons to Complex I of the mitochondrial electron transport chain, driving ATP synthesis. NADP+ (the phosphorylated form) functions similarly in anabolic reactions. These reactions don't consume NAD+ — it's reduced then re-oxidized in a cycle.
Non-redox substrate consumption (irreversible): Three enzyme families consume NAD+ stoichiometrically: - Sirtuins (SIRT1-7): NAD+-dependent deacetylases. SIRT1 removes acetyl groups from FOXO, p53, NF-κB, and PGC-1α, affecting gene expression for longevity, stress resistance, and mitochondrial biogenesis. SIRT3 deacetylates mitochondrial proteins, enhancing ETC efficiency. Each reaction destroys one NAD+ molecule. - PARPs (PARP1-3): consume NAD+ for DNA strand break repair by attaching ADP-ribose polymers to repair proteins. In chronic DNA damage states (aging, oxidative stress), PARPs compete with sirtuins for the same NAD+ pool. - CD38: an ectoenzyme that degrades NAD+ to generate cyclic ADP-ribose (calcium signaling) and ADPR. CD38 is upregulated in aging, inflammation, cancer, and metabolic dysfunction — and is the dominant NAD+ consumer in these states.
The aging depletion cascade: NAMPT activity declines with age and inflammation. CD38 upregulates with inflammation and aging. The result: declining production + accelerating consumption = NAD+ deficiency that compounds over time.
NNMT parallel drain: Nicotinamide N-methyltransferase (NNMT) methylates nicotinamide in adipose tissue, removing it from the NAD+ salvage pathway. In metabolic syndrome and obesity, NNMT is upregulated — this is the second major drain alongside CD38. 5-Amino-1MQ selectively inhibits NNMT in adipose without affecting hepatic methylation, preserving nicotinamide for NAD+ synthesis specifically in fat tissue.
Sirtuin-PARP competition: In states of chronic DNA damage or inflammation, PARP activation drains NAD+ before sirtuins can use it. Anti-inflammatory protocols and reducing oxidative DNA damage are thus complementary to NAD+ supplementation — they reduce PARP competition and allow more NAD+ to flow through the sirtuin pathway.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
NAD+ levels decline approximately 50% by age 50 in humans
Animal data is more consistent than human data for tissue-specific declines. The 50% figure is widely cited but should be qualified as primarily blood/muscle-specific in humans. Meta-analysis; Nature Metabolism 2025 review. n represents multiple pooled studies, not a single trial.
NMN at 1000mg/day for 60 days raised intracellular NAD+ from 18.4 µM to 45.3 µM in a depleted individual
Community n=1 with quantitative before/after measurement. Not a controlled trial but provides dose-response data in a depleted individual that clinical trials typically don't stratify for.
NMN supplementation improves insulin sensitivity and lipid profiles in metabolically impaired populations
Effects are more pronounced in metabolically impaired vs healthy populations. Not all trials show significant effects. Healthy, non-obese populations show smaller glucose/lipid improvements. Meta-analysis of 15+ RCTs; n varies by trial. Current Diabetes Reports 2024 review.
Diminishing returns observed above 500mg/day NMN for intracellular NAD+ elevation
Consistent with NAMPT rate-limiting kinetics: NAMPT converts NMN to NAD+ at a maximum rate regardless of substrate excess. Community data corroborates the saturation kinetics. Multiple independent Jinfiniti-tested n=1 experiments; diminishing returns pattern consistent across accounts.
80% subjective response rate in post-COVID fatigue patients with IV NAD+ therapy
Practitioner-reported clinical observation, not an RCT. High response rate consistent with the mechanism: post-viral mitochondrial dysfunction and CD38 activation directly targeted by NAD+ restoration. Not generalizable without controlled trials. Non-controlled prospective case series; n not precisely reported.
NR supplementation associated with reduced arterial stiffness age and improved cognition in n=1 experiment
Pre-Jinfiniti era experiment; no intracellular NAD+ measurement. Subjective and pseudobjective measures only (biological age tests, self-reported cognition, sleep quality changes). Historical but methodologically honest account.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.